drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
Humanized IgG1 bispecific antibody targeting GPRC5D on myeloma/plasma cells and CD3 on T cells; administered subcutaneously to engage T cells and redirect cytotoxicity against GPRC5D-expressing malignant plasma cells in relapsed/refractory multiple myeloma.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Antibodies, Bispecific
drug_category
BISPECIFIC T ENGAGER
drug_class
Engager
drug_delivery_route
Subcutaneous
drug_mechanism_of_action
Humanized IgG1 bispecific antibody that simultaneously binds GPRC5D on myeloma/plasma cells and CD3 on T cells, bringing T cells into proximity with tumor cells to form an immune synapse and activate T-cell mediated cytotoxicity against GPRC5D-expressing malignant plasma cells.
drug_name
QLS32015
nct_id_drug_ref
NCT05920876